Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 4/20 | 0.33 |
| ▸ | GAA | P10253 | 3/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10409249 | 0.82 | CYP3A4 (0.39) | CYP3A4ALOX15CASP1CASP7SMN1; SMN2 | |
| SCHEMBL5837003 | 0.80 | CYP3A4 (0.38) | CYP3A4ALOX15CASP1CASP7SMN1; SMN2 | |
| SCHEMBL2202080 | 0.75 | CYP3A4 (0.47) | CYP3A4ALOX15CASP1CASP7SMN1; SMN2 | |
| SCHEMBL70170 | 0.75 | TSHR (0.50) | CYP3A4ALOX15CASP1CASP7SMN1; SMN2 | |
| SCHEMBL895143 | 0.75 | CYP3A4 (0.47) | CYP3A4ALOX15CASP1CASP7SMN1; SMN2 | |
| Fluoride SCHEMBL7548973 | 0.73 | TSHR (0.48) | CYP3A4ALOX15CASP1CASP7SMN1; SMN2 | |
| Bromide SCHEMBL15303887 | 0.73 | TSHR (0.48) | CYP3A4ALOX15CASP1CASP7SMN1; SMN2 | |
| Methane SCHEMBL27563519 | 0.73 | TSHR (0.48) | CYP3A4ALOX15CASP1CASP7SMN1; SMN2 | |
| SCHEMBL4706664 | 0.73 | CYP3A4 (0.45) | CYP3A4ALOX15CASP1CASP7SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL2860732 | 0.73 | TSHR (0.48) | CYP3A4ALOX15CASP1CASP7SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3371190-B1 | HETEROCYCLIC COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORP (US) | 2022-03-30 | — | — | EP | disclosed |
| EP-3458458-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | Aptinyx Inc. (US) | 2019-03-27 | — | — | EP | disclosed |
| EP-3397629-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VPS-3, Inc. (US) | 2018-11-07 | — | — | EP | disclosed |
| US-20180290976-A1 | LSD1 INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. | 2018-10-11 | — | — | US | disclosed |
| EP-3341374-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO NTRK | Blueprint Medicines Corporation (US) | 2018-07-04 | — | — | EP | disclosed |
| EP-3283473-A1 | GHRELIN O-ACYL TRANSFERASE INHIBITORS | Eli Lilly and Company (US) | 2018-02-21 | — | — | EP | disclosed |
| WO-2017201283-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017117393-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2017-07-06 | — | — | WO | disclosed |
| WO-2017035354-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO NTRK | BLUEPRINT MEDICINES CORPORATION (US) | 2017-03-02 | — | — | WO | disclosed |
| WO-2016168222-A1 | GHRELIN O-ACYL TRANSFERASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2016-10-20 | — | — | WO | disclosed |
| EP-1732612-A1 | TRIPARTITE CONJUGATES CONTAINING A STRUCTURE INTERACTING WITH CELL MEMBRANE RAFTS AND THEIR USE | Jadolabs Gmbh (DE) | 2006-12-20 | — | — | EP | disclosed |
| WO-2006091697-A1 | DOPAMINE TRANSPORTER INHIBITORS FOR USE IN TREATMENT OF MOVEMENT DISORDERS AND OTHER CNS INDICATIONS | PSYCHENOMICS, INC. (US) | 2006-08-31 | — | — | WO | disclosed |
| WO-2005016884-A9 | CYCLOPROPYL DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | LUNDBECK & CO AS H (DK) | 2006-03-16 | — | — | WO | disclosed |
| US-20060009497-A1 | Novel tetrahydropyridine derivatives as renin inhibitors | ACTELION PHARMACEUTICALS, LTD. (CH) | 2006-01-12 | — | — | US | disclosed |
| WO-2005097199-A1 | TRIPARTITE CONJUGATES CONTAINING A STRUCTURE INTERACTING WITH CELL MEMBRANE RAFTS AND THEIR USE | JADOLABS GMBH (DE) | 2005-10-20 | — | — | WO | disclosed |
| US-20050113563-A1 | Chemical peptide ligation with three or more components | ASTRAZENECA PHARMACEUTICALS LP | 2005-05-26 | — | — | US | disclosed |
| US-6825350-B2 | ADMINISTERING DOSAGE OF IMMUNOLOGY RESPONSE MODERATOR | 3M INNOVATIVE PROPERTIES COMPANY | 2004-11-30 | — | — | US | disclosed |
| US-20030027850-A1 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | ASHWELL SUSAN (US) | 2003-02-06 | — | — | US | disclosed |
| US-6353099-B1 | USED FOR PREVENTION OR TREATMENT OF DISEASES, DISORDERS, CONDITIONS OR SYMPTOMS MEDIATED BY CELL ADHESION IN MAMMAL | MERCK & CO., INC. | 2002-03-05 | — | — | US | disclosed |
| US-6271225-B1 | PSYCHOLOGICAL DISORDERS | WELFIDE CORPORATION (JP) | 2001-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113563-A1 | Chemical peptide ligation with three or more components | VIP, IAPP, DNPEP | CYP3A4 4567/4885ALOX15 3900/4885CASP1 4303/4885 |
| US-20030027850-A1 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, L1CAM | CYP3A4 1349/4885ALOX15 271/4885CASP1 3008/4885 |
| US-20180290976-A1 | LSD1 INHIBITORS AND USES THEREOF | KDM1B, KDM1A, KDM2A | CYP3A4 1324/4885ALOX15 1882/4885CASP1 3315/4885 |
| US-20060009497-A1 | Novel tetrahydropyridine derivatives as renin inhibitors | REN, ACE, ACE2 | CYP3A4 181/4885ALOX15 3362/4885CASP1 3249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.